Investor Presentaiton
Emerging Markets Formulations business
Base business continued to display growth
EM Formulations Sales
(Rs. mn)
2,914
2,750
2,499
Q4 FY22 Revenue
Contribution
EM Formulations Sales
(Rs. mn)
"
11,921
10,167
7%
zydus
Dedicated To Life
ā
Highlights for the quarter
Excluding COVID opportunities, the business grew by
29% on a YoY basis.
Robust performance in key markets of Latin America,
Philippines and Vietnam drove overall performance of
the business.
However, the situation remained challenging for
business growth in Sri Lanka in the light of ongoing
political crisis. We remained vigilant to secure our
receivables and offset the impact of currency decline
through price hikes.
Q4FY21
Q3FY22
Q4FY22
FY21
FY22
YOY
10.0%
Q4 FY22 Gr.
FY22 Gr.
17.3%
QoQ
-5.6%
6View entire presentation